Cologuard® revenue increased 78 percent to $103 million during second quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Dow rise after Warsh says inflation risks have eased
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil falls as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Taiwan prosecutors detain Super Micro employees over chip exports
Exact Sciences (EXAS) PT Lowered to $65 at Cowen; Buy on Weakness
August 2, 2018 7:56 AM EDTCowen lowered its price target on Exact Sciences (NASDAQ: EXAS) to $65.00 (from $85.00) while maintaining a Outperform rating following Q2 miss.
Analyst Doug Schenkel commented, "EXAS missed Q2 revenue and volume expectations. While we think this could have been better explained, further... More
Exact Sciences (EXAS) Tops Q2 EPS by 3c, Revs Miss; Maintains Outlook
August 1, 2018 4:09 PM EDTExact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $102.9 million versus the consensus estimate of $104.66 million.
GUIDANCE:
Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus... More
